1. Home
  2. WBX vs DSGN Comparison

WBX vs DSGN Comparison

Compare WBX & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WBX
  • DSGN
  • Stock Information
  • Founded
  • WBX 2015
  • DSGN 2017
  • Country
  • WBX Spain
  • DSGN United States
  • Employees
  • WBX N/A
  • DSGN N/A
  • Industry
  • WBX Industrial Specialties
  • DSGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • WBX Consumer Discretionary
  • DSGN Health Care
  • Exchange
  • WBX Nasdaq
  • DSGN Nasdaq
  • Market Cap
  • WBX 102.7M
  • DSGN 208.9M
  • IPO Year
  • WBX N/A
  • DSGN 2021
  • Fundamental
  • Price
  • WBX $5.65
  • DSGN $3.77
  • Analyst Decision
  • WBX Buy
  • DSGN Hold
  • Analyst Count
  • WBX 3
  • DSGN 1
  • Target Price
  • WBX $0.72
  • DSGN $4.00
  • AVG Volume (30 Days)
  • WBX 496.2K
  • DSGN 82.2K
  • Earning Date
  • WBX 07-31-2025
  • DSGN 08-04-2025
  • Dividend Yield
  • WBX N/A
  • DSGN N/A
  • EPS Growth
  • WBX N/A
  • DSGN N/A
  • EPS
  • WBX N/A
  • DSGN N/A
  • Revenue
  • WBX $171,352,140.00
  • DSGN N/A
  • Revenue This Year
  • WBX N/A
  • DSGN N/A
  • Revenue Next Year
  • WBX $44.10
  • DSGN N/A
  • P/E Ratio
  • WBX N/A
  • DSGN N/A
  • Revenue Growth
  • WBX 3.75
  • DSGN N/A
  • 52 Week Low
  • WBX $0.23
  • DSGN $2.60
  • 52 Week High
  • WBX $5.99
  • DSGN $7.77
  • Technical
  • Relative Strength Index (RSI)
  • WBX 34.74
  • DSGN 47.59
  • Support Level
  • WBX $5.80
  • DSGN $3.33
  • Resistance Level
  • WBX $6.36
  • DSGN $4.21
  • Average True Range (ATR)
  • WBX 0.64
  • DSGN 0.24
  • MACD
  • WBX -0.06
  • DSGN -0.03
  • Stochastic Oscillator
  • WBX 38.62
  • DSGN 42.29

About WBX Wallbox N.V.

Wallbox NV is a smart electric vehicle charging and energy management company. It creates smart charging system combining technology design that manages the communication between user, vehicle, grid, building, and charger. The company is engaged in designing, manufacturing, and distributing faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA) which is also its key revenue generating segment, North America, and Asia‑Pacific.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: